Profile data is unavailable for this security.
About the company
Avantium NV, formerly Avantium Holding BV, is a company based in the Netherlands engaged in environmental research and development (R&D). The Company develops chemical technologies and production processes to convert bio-based feedstock into sustainable products. The Company's business comprises three segments: Catalysis, Renewable Chemistries, and YXY. Catalysis segment provides catalysis R&D services and systems to chemical, refinery and energy companies, utilizing its Flowrence Technology Platform to devise the appropriate catalyst testing solutions. Renewable Chemistries is the development division with a portfolio of projects focusing on the conversion of biomass to chemical building blocks and plastic materials. The YXY segment comprises the activities of Syviana, the joint venture with BASF SE. The YXY technology is used to convert plant-based sugars into chemical building blocks for plastics, such as polymer polyethylenefuranoate (PEF), and other applications.
- Revenue in EUR (TTM)19.70m
- Net income in EUR-31.40m
- Incorporated2000
- Employees262.00
- LocationAvantium NVZekeringstraat 29AMSTERDAM 1014 BVNetherlandsNLD
- Phone+31 205868080
- Fax+31 205868085
- Websitehttps://www.avantium.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Egetis Therapeutics AB (publ) | 5.40m | -28.13m | 189.33m | 30.00 | -- | 4.66 | -- | 35.03 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Newron Pharmaceuticals SpA | 9.04m | -16.19m | 189.61m | 23.00 | -- | -- | -- | 20.98 | -0.8991 | -0.8991 | 0.5019 | -1.66 | 0.2873 | -- | 4.57 | 389,414.50 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Allergy Therapeutics plc | 62.58m | -59.00m | 190.42m | 635.00 | -- | 6.12 | -- | 3.04 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Fine Foods & Pharmaceuticals NTM SpA | 251.81m | -3.52m | 194.13m | 753.00 | -- | 1.70 | 15.40 | 0.7709 | -0.1678 | -0.1678 | 11.51 | 5.18 | 0.9303 | 4.42 | 6.51 | 334,411.40 | -1.30 | -0.3116 | -1.98 | -0.4418 | 27.32 | 27.88 | -1.40 | -0.3935 | 0.6802 | 2.34 | 0.3434 | -- | 21.73 | 12.56 | 62.93 | -- | -26.87 | 3.71 |
| Xlife Sciences AG | 997.25k | 15.01m | 196.22m | 17.00 | 28.00 | 0.7111 | 7.69 | 196.76 | 1.22 | 1.22 | 0.1382 | 47.95 | 0.002 | -- | 0.2044 | 58,143.53 | 1.85 | -- | 2.33 | -- | 45.43 | -- | 938.17 | -- | -- | -- | 0.1345 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
| Celon Pharma SA | 50.73m | -6.59m | 199.24m | 513.00 | -- | 1.91 | 30.37 | 3.93 | -0.5508 | -0.5508 | 4.24 | 8.73 | 0.3574 | 2.08 | 7.23 | -- | -4.64 | -2.24 | -5.57 | -2.57 | 68.92 | 70.71 | -12.99 | -7.79 | 1.89 | -- | 0.0543 | -- | 11.29 | 11.57 | 28.40 | -- | -13.42 | -- |
| Probi AB | 52.28m | -51.80k | 201.00m | 167.00 | -- | 1.64 | 24.34 | 3.84 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -31.06m | 201.30m | 34.00 | -- | -- | -- | -- | -0.4053 | -0.4053 | 0.00 | -0.1883 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Genovis AB | 10.93m | 2.64m | 201.40m | 36.00 | 76.29 | 11.41 | 56.47 | 18.43 | 0.4686 | 0.4686 | 1.94 | 3.13 | 0.5084 | -- | -- | 3,432,784.00 | 12.28 | 18.56 | 13.37 | 21.45 | 66.09 | 65.51 | 24.15 | 23.88 | -- | -- | 0.2769 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| Avantium NV | 19.70m | -31.40m | 206.36m | 262.00 | -- | 2.89 | -- | 10.48 | -0.631 | -0.631 | 0.3851 | 0.8947 | 0.1005 | 2.27 | 1.84 | 75,190.84 | -17.42 | -23.26 | -23.76 | -30.61 | 83.07 | 83.15 | -173.35 | -186.67 | 1.00 | -- | 0.6689 | -- | 10.51 | 11.79 | -11.64 | -- | 61.87 | -- |
| Innate Pharma SA | 51.90m | -7.57m | 206.60m | 179.00 | -- | 3.98 | -- | 3.98 | -0.0939 | -0.0939 | 0.6451 | 0.642 | 0.2648 | -- | 5.67 | 289,949.70 | -3.86 | -8.83 | -4.87 | -12.11 | 94.50 | 93.17 | -14.59 | -55.55 | -- | -- | 0.6408 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| 4Basebio PLC | 415.95k | -7.37m | 211.40m | -- | -- | 50.74 | -- | 508.23 | -0.5094 | -0.5094 | 0.0287 | 0.2769 | 0.0296 | 0.3977 | 4.88 | -- | -52.42 | -- | -60.21 | -- | 80.51 | -- | -1,772.60 | -- | 3.28 | -40.29 | 0.6683 | -- | -20.71 | -- | -59.20 | -- | -- | -- |
| hVIVO PLC | 65.85m | 18.94m | 211.85m | 274.00 | 11.33 | 5.25 | 9.57 | 3.22 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Hansa Biopharma AB | 14.27m | -72.70m | 218.88m | 166.00 | -- | -- | -- | 15.33 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Laboratorio Reig Jofre SA | 323.88m | 8.85m | 221.72m | 1.32k | 24.57 | 1.04 | 9.85 | 0.6846 | 0.1115 | 0.1115 | 4.11 | 2.63 | -- | -- | -- | 246,110.20 | -- | 2.14 | -- | 2.79 | 58.04 | 61.39 | 2.73 | 2.65 | 0.8906 | 7.22 | 0.2219 | -- | 16.57 | 11.86 | 16.04 | 0.3019 | -9.54 | -- |
| Alliance Pharma plc | 199.81m | -8.29m | 222.24m | 249.00 | -- | 0.6826 | 60.39 | 1.11 | -0.0131 | -0.0131 | 0.3145 | 0.5127 | 0.3202 | 2.88 | 4.40 | 682,927.70 | -1.33 | 2.64 | -1.47 | 2.95 | 57.58 | 63.38 | -4.15 | 8.35 | 1.38 | 2.18 | 0.31 | 53.41 | 2.58 | 10.50 | -87.21 | -49.62 | -25.78 | 5.94 |
Data as of May 22 2024. Currency figures normalised to Avantium NV's reporting currency: Euro EUR
9.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| APG Asset Management NVas of 31 Dec 2022 | 4.73m | 5.94% |
| Robeco Schweiz AGas of 29 Mar 2024 | 1.49m | 1.87% |
| Azimut Capital Management SGR SpAas of 28 Mar 2024 | 660.89k | 0.83% |
| Groupama Asset Management SAas of 29 Sep 2023 | 197.23k | 0.25% |
| Aktia Varainhoito Oyas of 30 Apr 2024 | 121.88k | 0.15% |
| Portzamparc Gestion SAas of 29 Feb 2024 | 120.00k | 0.15% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 64.36k | 0.08% |
| American Century Investment Management, Inc.as of 09 May 2024 | 54.31k | 0.07% |
| Dimensional Fund Advisors Ltd.as of 09 May 2024 | 26.53k | 0.03% |
| DFA Australia Ltd.as of 31 Mar 2024 | 13.34k | 0.02% |
More ▼
Data from 29 Feb 2024 - 16 May 2024Source: FactSet Research Systems Inc.
